Abstract: Objective Tostudy the curative effect of neoadjuvant chemotherapy with capecitabine as a benchmark for treating advancedgastric cancer by performing a meta-analysis of the publishedstudies, then provide statistical evidence for the clinical treatment of advancedgastric cancer. Methods The database of Pubmed, CBMdisc, Embase and Cochrane aidedwith manual retrieval and other retrievals were searchedtoscreen neoadjuvant chemotherapy containing capecitabine in the treatment of advancedgastric cancer in rand omizedcontrolledtrials (RCT). The RevMan5.2 software was usedfor meta-analysis after extracting the useful data. Results Eight rand omizedcontrolledtrials involveda total of 699 patients with advancedgastric cancer were studied. Of the 8 trials, 7 were publishedby Chinese, 1 were publishedby English. Of the 699 patients, 351 were treatedby neoadjuvant chemotherapy containing capecitabine, 348 were treatedby neoadjuvant chemotherapy excluding capecitabine or without treating by neoadjuvant chemotherapy. According tothe meta-analysis of the available information, there were statistical differences in 1-year survival rate, radical operation resection rate (RO), total operation rate (R1) (P＜ 0.05). The OR rate and 95% CI were 2.97 (1.79-4.91) for 1-year survival rate, 2.94 (2.03-4.26) for RO and 3.54 (2.31-5.43) for R1. Conclusion Comparedwith neoadjuvant chemotherapy excluding capecitabine or patients without neoadjuvant chemotherapy, neoadjuvant chemotherapy containing capecitabine can improve the 1-year survival rate, radical operation resection rate and total operation rate in patients with advancedgastric cancer.